Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gland

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    571 result(s) found for: Gland. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-001125-20 Sponsor Protocol Number: FIRM-ACT Start Date*: 2004-07-26
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: First International Randomized trial in Metastatic Adrenocortical Cancer Treatment FIRM-ACT Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane
    Medical condition: Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer in adults and children
    Disease: Version SOC Term Classification Code Term Level
    6.1 10001378 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001274-34 Sponsor Protocol Number: SG-ABI14 Start Date*: 2014-07-03
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers.
    Medical condition: relapsed and/or metastatic, castration resistant, salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10026677 Malignant salivary gland cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005090-65 Sponsor Protocol Number: VALPAX Start Date*: 2007-10-18
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours
    Medical condition: Patients with anaplastic thyroid cancer or with metastatic solid tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002240 Anaplastic thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005221-11 Sponsor Protocol Number: MUTAVA Start Date*: 2008-10-22
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel.
    Medical condition: Patients with undifferentiated thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002240 Anaplastic thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003068-28 Sponsor Protocol Number: 77946 Start Date*: 2021-09-29
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node detection of cervical occult lymph node metastases in patients with parotid gland carcinoma by means of sentinel node biopsy using 68-galium-tilmanocept PET-CT.
    Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with parotid gland carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026329 Malignant neoplasm of parotid gland LLT
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004629-96 Sponsor Protocol Number: S-20130147 Start Date*: 2014-06-13
    Sponsor Name:Department of Nuclear Medicine, Odense University Hospital
    Full Title: Diagnostic Modalities in Nuclear Medicine in Well-Differentiated Thyroid Cancer
    Medical condition: Well-differentiated Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001802-27 Sponsor Protocol Number: F002MH0218_1 Start Date*: 2019-04-16
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.
    Medical condition: Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    20.0 10014698 - Endocrine disorders 10001341 Adrenal cortical hyperfunctions HLT
    20.0 10014698 - Endocrine disorders 10001376 Adrenal neoplasms HLT
    20.0 100000004864 10001378 Adrenal neoplasms malignant HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002470-42 Sponsor Protocol Number: 72010 Start Date*: 2021-11-29
    Sponsor Name:Univeristy Medical Center Utrecht
    Full Title: Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: A proof of concept study
    Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with thyroid carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004295-19 Sponsor Protocol Number: 1209-EnTF Start Date*: 2014-10-08
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t...
    Medical condition: Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed) NL (Completed) DK (Completed) FR (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004408-36 Sponsor Protocol Number: HN02-UC-0130/1205 Start Date*: 2013-03-12
    Sponsor Name:UNICANCER
    Full Title:
    Medical condition: _
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003668-11 Sponsor Protocol Number: E7080-G000-604 Start Date*: 2018-07-30
    Sponsor Name:Eisai Ltd.
    Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored...
    Medical condition: solid tumors or lymphomas, as defined in parent protocol
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025315 Lymphoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-000422-58 Sponsor Protocol Number: D4203C00011 Start Date*: 2013-07-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated T...
    Medical condition: Papillary Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071029 Thyroid cancer stage III PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071030 Thyroid cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072162 Thyroid cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) IT (Completed) ES (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005366-17 Sponsor Protocol Number: 2020/ABM/01/00100 Start Date*: 2022-09-14
    Sponsor Name:Medical University of Bialystok
    Full Title: Evaluation of METtformin effect on the fertility of patients treated with 131I for THYRoid cancer – METHYR Study.
    Medical condition: Thyroid papilare cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001032-12 Sponsor Protocol Number: PANTHERA Start Date*: 2008-10-28
    Sponsor Name:Universitätsklinikum Schleswig-Holstein
    Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2012-003814-15 Sponsor Protocol Number: 2012-784 Start Date*: 2013-03-06
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancers
    Medical condition: Follicular or poorly differentiated cancer refractory to radio iodine
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022677-34 Sponsor Protocol Number: EMR200109-619 Start Date*: 2011-09-07
    Sponsor Name:Dekan des Fachbereichs Humanmedizin
    Full Title: Influence of high dose vitamin D substitution on humoral immunity and lymphocyte function in patients with type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Medical condition: Type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004570-34 Sponsor Protocol Number: 01045-ATLEP Start Date*: 2018-11-15
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvat...
    Medical condition: Anaplastic (ATC) or Poorly Differentiated Thyroid Carcinoma (PDTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076603 Poorly differentiated thyroid carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003227-21 Sponsor Protocol Number: SGC-AX14 Start Date*: 2014-10-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori Milano
    Full Title: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract
    Medical condition: recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004450-27 Sponsor Protocol Number: THYR01605 Start Date*: 2006-05-02
    Sponsor Name:GENZYME
    Full Title: Follow-up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method
    Medical condition: Follow-up of Thyroid Cancer Patients from Study THYR-008-00
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043738 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002846-38 Sponsor Protocol Number: OXC4T4-302 Start Date*: 2007-12-06
    Sponsor Name:OXiGENE, Inc.
    Full Title: A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with pacli...
    Medical condition: Anaplastic Thyroid Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002240 Anaplastic thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:16:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA